Display options
Cite
Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis. Ont Health Technol Assess Ser. 2009;9(1):1-90
(2009). Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis. Ontario health technology assessment series, 9(1), 1-90.
"Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis." Ontario health technology assessment series vol. 9,1 (2009): 1-90.
Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis. Ont Health Technol Assess Ser. 2009;9(1):1-90. Epub 2009 Apr 01. PMID: 23074513; PMCID: PMC3385416.
Copy Download .nbib Format: NLM
Share it on

Ont Health Technol Assess Ser. 2009;9(1):1-90. Epub 2009 Apr 01.

Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis.

Ontario health technology assessment series

[No authors listed]

PMID: 23074513 PMCID: PMC3385416

Abstract

OBJECTIVE: The purpose of this project was to determine the role of corneal implants in the management of corneal thinning disease conditions. An evidence-based review was conducted to determine the safety, effectiveness and durability of corneal implants for the management of corneal thinning disorders. The evolving directions of research in this area were also reviewed. SUBJECT OF THE EVIDENCE-BASED ANALYSIS: The primary treatment objectives for corneal implants are to normalize corneal surface topography, improve contact lens tolerability, and restore visual acuity in order to delay or defer the need for corneal transplant. Implant placement is a minimally invasive procedure that is purported to be safe and effective. The procedure is also claimed to be adjustable, reversible, and both eyes can be treated at the same time. Further, implants do not limit the performance of subsequent surgical approaches or interfere with corneal transplant. The evidence for these claims is the focus of this review. The specific research questions for the evidence review were as follows: SafetyCorneal Surface Topographic Effects:Effects on corneal surface remodellingImpact of these changes on subsequent interventions, particularly corneal transplantation (penetrating keratoplasty [PKP])Visual AcuityRefractive OutcomesVISUAL QUALITY (SYMPTOMS): such as contrast vision or decreased visual symptoms (halos, fluctuating vision)Contact lens toleranceFunctional visual rehabilitation and quality of lifePatient satisfaction:Disease Process:Impact on corneal thinning processEffect on delaying or deferring the need for corneal transplantation

CLINICAL NEED: TARGET POPULATION AND CONDITION Corneal ectasia (thinning) comprises a range of disorders involving either primary disease conditions such as keratoconus and pellucid marginal corneal degeneration or secondary iatrogenic conditions such as corneal thinning occurring after LASIK refractive surgery. The condition occurs when the normally round dome-shaped cornea progressively thins causing a cone-like bulge or forward protrusion in response to the normal pressure of the eye. Thinning occurs primarily in the stoma layers and is believed to be a breakdown in the collagen network. This bulging can lead to an irregular shape or astigmatism of the cornea and, because the anterior part of the cornea is largely responsible for the focusing of light on the retina, results in loss of visual acuity. This can make even simple daily tasks, such as driving, watching television or reading, difficult to perform. Keratoconus (KC) is the most common form of corneal thinning disorder and is a noninflammatory chronic disease process. Although the specific causes of the biomechanical alterations that occur in KC are unknown, there is a growing body of evidence to suggest that genetic factors may play an important role. KC is a rare condition (<0.05% of the population) and is unique among chronic eye diseases as it has an early age of onset (median age of 25 years). Disease management for this condition follows a step-wise approach depending on disease severity. Contact lenses are the primary treatment of choice when there is irregular astigmatism associated with the disease. When patients can no longer tolerate contact lenses or when lenses no longer provide adequate vision, patients are referred for corneal transplant. Keratoconus is one of the leading indications for corneal transplants and has been so for the last three decades. Yet, despite high graft survival rates of up to 20 years, there are reasons to defer receiving transplants for as long as possible. Patients with keratoconus are generally young and life-long term graft survival would be an important consideration. The surgery itself involves lengthy time off work and there are potential complications from long term steroid use following surgery, as well as the risk of developing secondary cataracts, glaucoma etc. After transplant, recurrent KC is possible with need for subsequent intervention. Residual refractive errors and astigmatism can remain challenging after transplantation and high refractive surgery rates and re-graft rates in KC patients have been reported. Visual rehabilitation or recovery of visual acuity after transplant may be slow and/or unsatisfactory to patients.

DESCRIPTION OF TECHNOLOGY/THERAPY: INTACS® (Addition Technology Inc. Sunnyvale, CA, formerly KeraVision, Inc.) are the only currently licensed corneal implants in Canada. The implants are micro-thin poly methyl methacrylate crescent shaped ring segments with a circumference arc length of 150 degrees, an external diameter of 8.10 mm, an inner diameter of 6.77 mm, and a range of different thicknesses. Implants act as passive spacers and, when placed in the cornea, cause local separation of the corneal lamellae resulting in a shortening of the arc length of the anterior corneal curvature and flattening the central cornea. Increasing segment thickness results in greater lamellar separation with increased flattening of the cornea correcting for myopia by decreasing the optical power of the eye. Corneal implants also improve corneal astigmatism but the mechanism of action for this is less well understood. Treatment with corneal implants is considered for patients who are contact lens intolerant, having adequate corneal thickness particularly around the area of the implant incision site and without central corneal scarring. Those with central corneal scarring would not benefit from implants and those without an adequate corneal thickness, particularly in the region that the implants are being inserted, would be at increased risk for corneal perforation. Patients desiring to have visual rehabilitation that does not include glasses or contact lenses would not be candidates for corneal ring implants. Placement of the implants is an outpatient procedure with topical anesthesia generally performed by either corneal specialists or refractive surgeons. It involves creating tunnels in the corneal stroma to secure the implants either by a diamond knife or laser calibrated to an approximate depth of 70% of the cornea. Variable approaches have been employed by surgeons in selecting ring segment size, number and position. Generally, two segments of equal thickness are placed superiorly and inferiorly to manage symmetrical patterns of corneal thinning whereas one segment may be placed to manage asymmetric thinning patterns. Following implantation, the major safety concerns are for potential adverse events including corneal perforation, infection, corneal infiltrates, corneal neovascularization, ring migration and extrusion and corneal thinning. Technical results can be unsatisfactory for several reasons. Treatment may result in an over or under-correction of refraction and may induce astigmatism or asymmetry of the cornea. Progression of the corneal cone with corneal opacities is also invariably an indication for progression to corneal transplant. Other reasons for treatment failure or patient dissatisfaction include foreign body sensation, unsatisfactory visual quality with symptoms such as double vision, fluctuating vision, poor night vision or visual side effects related to ring edge or induced or unresolved astigmatism.

EVIDENCE-BASED ANALYSIS METHODS: The literature search strategy employed keywords and subject headings to capture the concepts of 1) intrastromal corneal rings and 2) corneal diseases, with a focus on keratoconus, astigmatism, and corneal ectasia. The initial search was run on April 17, 2008, and a final search was run on March 6, 2009 in the following databases: Ovid MEDLINE (1996 to February Week 4 2009), OVID MEDLINE In-Process and Other Non-Indexed Citations, EMBASE (1980 to 2009 Week 10), OVID Cochrane Library, and the Centre for Reviews and Dissemination/International Agency for Health Technology Assessment. Parallel search strategies were developed for the remaining databases. Search results were limited to human and English-language published between January 2000 and April 17, 2008. The resulting citations were downloaded into Reference Manager, v.11 (ISI Researchsoft, Thomson Scientific, U.S.A), and duplicates were removed. The Web sites of several other health technology agencies were also reviewed including the Canadian Agency for Drugs and Technologies in Health (CADTH), ECRI, and the United Kingdom National Institute for Clinical Excellence (NICE). The bibliographies of relevant articles were scanned.

INCLUSION CRITERIA: English language reports and human studiesAny corneal thinning disorderReports with corneal implants used alone or in conjunction with other interventionsOriginal reports with defined study methodologyReports including standardized measurements on outcome events such as technical success, safety, effectiveness, durability, vision quality of life or patient satisfactionCase reports or case series for complications and adverse events

EXCLUSION CRITERIA: Non-systematic reviews, letters, comments and editorialsReports not involving outcome events such as safety, effectiveness, durability, vision quality or patient satisfaction following an intervention with corneal implantsReports not involving corneal thinning disorders and an intervention with corneal implants

SUMMARY OF FINDINGS: In the MAS evidence review on intrastromal corneal ring implants, 66 reports were identified on the use of implants for management of corneal thinning disorders. Reports varied according to their primary clinical indication, type of corneal implant, and whether or not secondary procedures were used in conjunction with the implants. Implants were reported to manage post LASIK thinning and/or uncorrected refractive error and were also reported as an adjunctive intervention both during and after corneal transplant to manage recurrent thinning and/or uncorrected refractive error. (ABSTRACT TRUNCATED)

References

  1. Ophthalmology. 2003 May;110(5):1031-40 - PubMed
  2. Ophthalmology. 2003 Jul;110(7):1396-402 - PubMed
  3. J Cataract Refract Surg. 2006 Dec;32(12):2039-42 - PubMed
  4. J Am Optom Assoc. 1999 Aug;70(8):515-24 - PubMed
  5. Eye Contact Lens. 2008 Jul;34(4):211-4 - PubMed
  6. J Cataract Refract Surg. 2007 Mar;33(3):528-30 - PubMed
  7. Trans Am Ophthalmol Soc. 2006;104:212-20 - PubMed
  8. Am J Ophthalmol. 2006 May;141(5):891-5 - PubMed
  9. J Cataract Refract Surg. 2002 Nov;28(11):1947-51 - PubMed
  10. J Refract Surg. 2004 Nov-Dec;20(6):818-22 - PubMed
  11. J Refract Surg. 2006 Jun;22(6):539-45 - PubMed
  12. J Cataract Refract Surg. 2007 Jul;33(7):1303-14 - PubMed
  13. J Cataract Refract Surg. 2006 Jun;32(6):978-85 - PubMed
  14. Arch Ophthalmol. 2003 Mar;121(3):322-6 - PubMed
  15. Cornea. 2000 Jan;19(1):7-11 - PubMed
  16. J Cataract Refract Surg. 2002 Sep;28(9):1568-74 - PubMed
  17. Cornea. 2003 Mar;22(2):122-5 - PubMed
  18. Am J Ophthalmol. 2003 May;135(5):620-7 - PubMed
  19. Curr Opin Ophthalmol. 2006 Aug;17(4):406-12 - PubMed
  20. J Cataract Refract Surg. 2006 Apr;32(4):676-8 - PubMed
  21. J Cataract Refract Surg. 2001 Feb;27(2):287-96 - PubMed
  22. J Refract Surg. 2007 Jan;23(1):93-5 - PubMed
  23. Ophthalmology. 2007 Sep;114(9):1643-52 - PubMed
  24. Ophthalmology. 2004 Mar;111(3):440-6 - PubMed
  25. Ophthalmic Physiol Opt. 2007 Nov;27(6):561-7 - PubMed
  26. J Cataract Refract Surg. 2006 Jun;32(6):986-92 - PubMed
  27. J Cataract Refract Surg. 2003 Feb;29(2):407-9 - PubMed
  28. J Refract Surg. 2004 Jul-Aug;20(4):349-55 - PubMed
  29. Int J Technol Assess Health Care. 1994 Fall;10(4):714-5 - PubMed
  30. J Cataract Refract Surg. 2004 Jan;30(1):230-3 - PubMed
  31. J Cataract Refract Surg. 2008 Sep;34(9):1521-6 - PubMed
  32. Am J Ophthalmol. 2008 May;145(5):775-9 - PubMed
  33. J Refract Surg. 2008 Sep;24(7):690-5 - PubMed
  34. Am J Ophthalmol. 2007 Feb;143(2):236-244 - PubMed
  35. Ophthalmology. 2003 Jun;110(6):1076-81 - PubMed
  36. Ophthalmology. 2001 Aug;108(8):1409-14 - PubMed
  37. Eye Contact Lens. 2008 Jul;34(4):238-41 - PubMed
  38. J Refract Surg. 2006 Oct;22(8):764-71 - PubMed
  39. Cornea. 2008 Jun;27(5):531-4 - PubMed
  40. J Cataract Refract Surg. 2003 Jun;29(6):1228-30 - PubMed
  41. Am J Ophthalmol. 2007 Sep;144(3):387-389 - PubMed
  42. Br J Ophthalmol. 2000 Jan;84(1):60-6 - PubMed
  43. Curr Opin Ophthalmol. 2008 Jul;19(4):307-8 - PubMed
  44. Cornea. 2007 Sep;26(8):956-62 - PubMed
  45. J Cataract Refract Surg. 2007 Jan;33(1):75-80 - PubMed
  46. Doc Ophthalmol. 2000;100(1):27-37 - PubMed
  47. Curr Opin Ophthalmol. 2007 Jul;18(4):284-9 - PubMed
  48. Ophthalmology. 2006 Nov;113(11):1909-17 - PubMed
  49. Eye Contact Lens. 2006 May;32(3):121-3 - PubMed
  50. J Cataract Refract Surg. 2003 Jul;29(7):1421-4 - PubMed
  51. J Refract Surg. 2003 Nov-Dec;19(6):645-53 - PubMed
  52. J Refract Surg. 2002 Sep-Oct;18(5):535-41 - PubMed
  53. J Cataract Refract Surg. 2004 Nov;30(11):2427-30 - PubMed
  54. J Cataract Refract Surg. 2007 Jan;33(1):69-74 - PubMed
  55. Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3791-5 - PubMed
  56. J Cataract Refract Surg. 2004 Aug;30(8):1802-4 - PubMed
  57. J Cataract Refract Surg. 2007 Oct;33(10):1808-10 - PubMed
  58. Ophthalmology. 2005 Apr;112(4):660-6 - PubMed
  59. Am J Ophthalmol. 2003 Jan;135(1):64-70 - PubMed
  60. Arch Ophthalmol. 2005 Nov;123(11):1604-7 - PubMed
  61. Am J Ophthalmol. 2005 Nov;140(5):926-7 - PubMed
  62. Clin Exp Ophthalmol. 2001 Dec;29(6):345-51 - PubMed
  63. Ophthalmology. 2006 Sep;113(9):1633-8 - PubMed
  64. J Refract Surg. 2005 May-Jun;21(3):218-22 - PubMed
  65. J Cataract Refract Surg. 2000 Oct;26(10):1473-9 - PubMed
  66. Cont Lens Anterior Eye. 2003 Dec;26(4):175-80 - PubMed
  67. J Cataract Refract Surg. 2007 Apr;33(4):648-53 - PubMed
  68. J Cataract Refract Surg. 2006 Oct;32(10):1710-6 - PubMed
  69. Eye Contact Lens. 2006 Mar;32(2):75-7 - PubMed
  70. J Cataract Refract Surg. 2004 Aug;30(8):1685-95 - PubMed
  71. J Cataract Refract Surg. 2006 Jun;32(6):993-8 - PubMed
  72. J Refract Surg. 2006 Nov;22(9):878-83 - PubMed
  73. J Cataract Refract Surg. 2006 May;32(5):837-45 - PubMed
  74. J Cataract Refract Surg. 2007 Nov;33(11):1886-91 - PubMed
  75. Am J Ophthalmol. 2004 Oct;138(4):527-35 - PubMed
  76. J Cataract Refract Surg. 2000 Aug;26(8):1117-22 - PubMed
  77. Arch Ophthalmol. 2005 Oct;123(10):1308-14 - PubMed
  78. Optometry. 2004 Jan;75(1):48-54 - PubMed
  79. Ophthalmology. 2000 Nov;107(11):2061-71 - PubMed
  80. Cornea. 2005 Nov;24(8):941-6 - PubMed
  81. Am J Ophthalmol. 1986 Mar 15;101(3):267-73 - PubMed
  82. J Cataract Refract Surg. 2006 May;32(5):747-55 - PubMed
  83. J Refract Surg. 2006 Mar;22(3):307-9 - PubMed
  84. BMJ. 2004 Jun 19;328(7454):1490 - PubMed
  85. Cornea. 2006 Jan;25(1):29-33 - PubMed
  86. Trans Am Ophthalmol Soc. 2007;105:214-23; discussion 223-4 - PubMed
  87. J Cataract Refract Surg. 2003 Apr;29(4):832-4 - PubMed
  88. Surv Ophthalmol. 1998 Jan-Feb;42(4):297-319 - PubMed
  89. J Refract Surg. 2007 Feb;23(2):205-8 - PubMed
  90. J Cataract Refract Surg. 2005 May;31(5):943-53 - PubMed
  91. J Cataract Refract Surg. 1998 Apr;24(4):456-63 - PubMed
  92. J Cataract Refract Surg. 2008 Jan;34(1):174 - PubMed
  93. Cornea. 2007 Dec;26(10):1282-4 - PubMed
  94. J Cataract Refract Surg. 2003 Feb;29(2):379-86 - PubMed
  95. J Refract Surg. 2005 May-Jun;21(3):296-8 - PubMed
  96. J Refract Surg. 2005 May-Jun;21(3):236-46 - PubMed
  97. J Refract Surg. 2006 Nov;22(9):910-3 - PubMed
  98. J Cataract Refract Surg. 2004 Apr;30(4):812-20 - PubMed
  99. Ophthalmology. 2001 Sep;108(9):1688-94 - PubMed
  100. Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2537-46 - PubMed
  101. J Refract Surg. 2002 Jan-Feb;18(1):43-6 - PubMed
  102. J Cataract Refract Surg. 2007 Mar;33(3):488-96 - PubMed
  103. J Cataract Refract Surg. 2001 Feb;27(2):277-86 - PubMed
  104. Eye Contact Lens. 2008 Jul;34(4):234-7 - PubMed
  105. J Cataract Refract Surg. 2001 Sep;27(9):1456-68 - PubMed
  106. J Cataract Refract Surg. 2007 Feb;33(2):247-53 - PubMed
  107. Cornea. 2004 Aug;23(6):547-9 - PubMed
  108. J Cataract Refract Surg. 2006 May;32(5):756-61 - PubMed
  109. J Cataract Refract Surg. 2008 May;34(5):796-801 - PubMed
  110. Ophthalmology. 2004 Apr;111(4):747-51 - PubMed
  111. J Cataract Refract Surg. 2003 Dec;29(12):2419-29 - PubMed

Publication Types